Orexigen Therapeutics Inc: Corporate And Strategic Assessment Report Company Strategy, Swot

Introduction

Introduction

Orexigen Therapeutics (Orexigen) focuses on the development and commercialization of therapeutics for central nervous system (CNS) disorders with initial focus on obesity. The company leverages its proprietary low-throughput screening model technology to screen drugs and combine approved generic drugs to create new therapeutics for CNS to improve energy expenditure.

Scope

*Contains corporate strategy, value chain presence and SWOT Analysis

*Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors

*Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Orexigen's innovative low-throughout screening model technology used in developing compositions for Contrave and Empatic was licensed from Oregon Health & Science University (OHSU), in 2003. Naltrexone and bupropion, which are the basic compounds for Contrave, are licensed from Dr. Lee G Dante, in 2004.

Orexigen derived revenues in 2006 from Cypress Biosciences for granting sublicense to Orexigen's licensed technology. Revenues decreased from $0.3 million in 2005 to $0.09 in 2006 primarily due to the expiry of the collaborative agreement with Eli Lilly in 2005.

Orexigen does not forecast any revenues during the period 2006-2010 as the company has no products to be launched and as well as any licensing agreement during 2006-2010. The only agreement for sublicensing technology to Cypress Biosciences (Cypress), for Obstructive Sleep Apnea treatment, was discontinued in 2006.

Reasons to Purchase

*Access all the important information and analysis on the company in a single report

*Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain

*Gain access to company's adjusted five year financial data along with key ratios and market capitalization

For more information please visit :

http://www.aarkstore.com/reports/Orexigen-Therapeutics-Inc-Corporate-and-Strategic-Assessment-Report-Company-Strategy-SWOT-Analysis-and-5-year-Adjusted-Financials-with-In-depth-Company-Profile-21142.html

by: Aarkstore Enterprise

POST COMMENT

Aarkstore Enterprise -sunopta Inc (soy) - Financial And Strategic Analysis Review Aarkstore Enterprise -sunsuper Pty Ltd - Strategic Analysis Review Aarkstore Enterprise -sunway City Berhad (suncity) - Financial And Strategic Analysis Review Aarkstore Enterprise -su-raj Diamonds And Jewellery Limited (507892) - Financial And Strategic Anal Aarkstore Enterprise -surana Corporation Limited (513597) - Financial And Strategic Analysis Review Strategic Thinking Series - Article 3 of 4 - Desired State Indian Logistics Sector : Strategic Assessment of Key Elements and Opportunities --- Aarkstore Enterprise Strategic Intuition The Creative Spark In Human Achievement Madras Cements Ltd. (500260) - Financial And Strategic Analysis Review Aarkstore Enterprise -magnitogorsk Metallurgicheskiy Kombinat Oao (magn) - Financial And Strategic Aarkstore Enterprise -malayan United Industries Berhad (muiind) - Financial And Strategic Analysis Manhattan Associates, Inc. (manh) - Financial And Strategic Analysis Review Mannai Corporation Q.s.c (mccs) - Financial And Strategic Analysis Review